Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, Toronto, Canada.
Department of Psychiatry, Hotchkiss Brain Institute and O'Brien Institute for Public Health University of Calgary, Calgary, Canada.
Alzheimers Dement. 2022 Nov;18(11):2199-2208. doi: 10.1002/alz.12519. Epub 2022 Feb 1.
Mild behavioral impairment (MBI) is characterized by later-life emergence of neuropsychiatric symptoms. Investigating its relationship with progression to Alzheimer's disease (AD) would provide insight on its importance as a predictor of AD.
Cognitively normal participants (N = 11,372) from the National Alzheimer's Coordinating Center were stratified by MBI status, using the Neuropsychiatric Inventory-Questionnaire. We investigated whether MBI and its domains were predictors of progression to clinically-diagnosed AD. MBI as a predictor of progression to neuropathology-confirmed AD was also investigated in those with neuropathological data.
Six percent (N = 671) of participants progressed to AD. MBI (N = 2765) was a significant predictor of progression to clinically-diagnosed (hazard ratio [HR] = 1.75) and neuropathology-confirmed AD (HR = 1.59). MBI domains were also associated with clinically-diagnosed AD, with psychosis having the greatest effect (HR = 6.49).
These findings support the biological underpinnings of MBI, emphasizing the importance of later life behavioral changes in dementia detection and prognostication.
轻度行为障碍(MBI)的特征是晚年出现神经精神症状。研究其与阿尔茨海默病(AD)进展的关系,可以深入了解其作为 AD 预测因子的重要性。
使用神经精神病学问卷(Neuropsychiatric Inventory-Questionnaire),对来自国家阿尔茨海默病协调中心的认知正常参与者(N=11372)进行 MBI 状态分层。我们调查了 MBI 及其各领域是否是向临床诊断为 AD 进展的预测因子。在有神经病理学数据的参与者中,还研究了 MBI 作为神经病理学证实的 AD 进展的预测因子。
6%(N=671)的参与者进展为 AD。MBI(N=2765)是向临床诊断为 AD(风险比 [HR]=1.75)和神经病理学证实的 AD(HR=1.59)进展的显著预测因子。MBI 各领域也与临床诊断为 AD 相关,精神病的影响最大(HR=6.49)。
这些发现支持 MBI 的生物学基础,强调了晚年行为变化在痴呆检测和预后中的重要性。